AGAVE-201 Trial Review
A hematologist provides an overview of the AGAVE-201 trial investigating axatilimab in patients with chronic graft-vs-host disease.
Video content above is prompted by the following questions:
- Please provide an overview of the AGAVE-201 trial, including its design, patient population, and key endpoints.
- What were the primary and secondary endpoints of the AGAVE-201 trial, and how were they assessed?
- How did the trial evaluate the efficacy, safety, and tolerability of different dosing regimens of axatilimab in patients with recurrent or refractory active chronic GVHD?
COMMANDS Trial Demonstrates Benefit Across Mutations in RS-Positive LR-MDS
October 23rd 2024During a Case-Based Roundtable® event, Yazan Madanat, MD, discussed a the patient population and outcomes of the COMMANDS trial of luspatercept in myelodysplastic syndrome in the first article of a 2-part series.
Read More
Lunning Evaluates CAR T-Cell Therapy for ASCT-Eligible and Ineligible DLBCL
September 22nd 2024During a Case-Based Roundtable® event, Matthew A. Lunning, DO, discussed the updated trial data for 2 chimeric antigen receptor T-cell therapies in patients with diffuse large B-cell lymphoma.
Read More
